Saturday, July 20, 2024


Remix Therapeutics Attains Near-Term Milestone from Roche Collaboration

Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, announced that it...

FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

Roche announced the United States Food and Drug Administration (US FDA) has approved the Vabysmo 6.0 mg single-dose prefilled syringe (PFS) for use in...

Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

Roche announced the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay,...

Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

Roche announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its cobas® liat SARS-CoV-2, Influenza A/B &...

Phanes Therapeutics, Inc. Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that it has entered into...

Hot Topics